Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026

Go back to Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026
AGENUS (NASDAQ: AGEN) Delayed: 6.19 --0 (-0%)
Previous Close $6.19    52 Week High $7.49 
Open $6.19    52 Week Low $2.61 
Day High $6.19    P/E N/A 
Day Low $6.19    EPS $-1.10 
Volume 26,548